What the DO-HEALTH Omega-3 Trial Actually Showed About Slowing Biological Aging
The DO-HEALTH omega-3 paper became one of those longevity studies that was easy to summarize too quickly. A daily gram […]
The Senolytics Pipeline in 2026: Where the Science Still Looks Strong — and Where It Doesn’t
Few ideas in longevity science remain as intuitively powerful as senolytics. If aging tissues accumulate senescent cells — damaged cells
Why Chronic Inflammation Keeps Moving to the Center of Longevity Science
For years, chronic inflammation sat in longevity science as both a familiar fact and a slightly unsatisfying explanation. Everyone knew
Why Longitudinal Data May Be the Real Moat in Longevity
Longevity companies often talk as if their advantage lies in a proprietary clock, a sharper scan, a larger omics panel,
Longevity Capital in 2026: The Four Buckets Still Getting Funded
There is a temptation to talk about longevity investing as if it were a single sector. It is not. The
Why Regulators Still Don’t Approve “Aging” — and What Longevity Startups Do Instead
For a field built on the idea that aging is the biggest upstream driver of chronic disease, the obvious commercial
What Counts as an Evidence-Based Longevity Clinic?
The phrase “longevity clinic” has become broad enough to mean almost anything: a luxury diagnostic package, a preventive-medicine program, a
Do We Actually Need Aging Clocks?
Few ideas in longevity science have spread faster than the promise of the aging clock. The sales pitch is simple
Why Longevity Trials Struggle With Endpoints — and What Researchers Are Using Instead
The most seductive endpoint in longevity science is also the least practical one: living longer. In mice, that is manageable.
Are GLP-1s the First Longevity Drugs — or Just the First Big Proxy?
Few drug classes have moved from endocrinology into so many neighboring territories so quickly. What began as a diabetes story